GP llb/llla receptor

Glycoprotein (GP llb/llla) receptor inhibitors abciximab eptifibatide... 

Coller BS Blockade of platelet GP llb/llla receptors as an antithrombotic strategy. Circulation 1995 92 2373-2380. 

Converse to UFH, the use of enoxaparin during PCI did not require anticoagulation monitoring, and there was no dose modification with concomitant GP llb-llla receptor blockers administration (9). 

Agonists of platelet activation promote conformational changes In GP llb/llla receptors that permit binding of fibrinogen. 

Fibrinogen simultaneously binds to GP llb/llla receptors on two separate platelets, resulting in aggregation. 

Early pharmacotherapy for NSTE ACS is. similar to that for STE ACS except that (1) fibrinolytic therapy is not administered (2) GP llb/llla receptor blockers are administered to high-risk patients and (3) there are no standard quahty performance measures for patients with NSTE ACS with UA. 

STEMI Trials Involving GP llb/llla Receptor Inhibitors... 

Fibrinogen and von Willebrand Factor are able to cross link platelets through binding to glycoprotein llb/llla receptors present on the surface of activated platelets, leading to their aggregation. Abbreviations-. Gp, glycoprotein RGD, Arg-Gly-Asp. 

Activation leads to the expression of glycoprotein (GP) llb/llla, the receptor for fibrinogen. This initiates formation of the fibrin plug. 

---